SB 112 would prohibit Montana state funds (including federal funds) from purchasing opioid reversal drugs after June 30, 2025, from companies involved in opioid settlement agreements. It allows existing contracts for these drugs to continue until fulfillment but bans renewal after the deadline, and requires continued supply under settlement agreements signed before September 1, 2024. The bill directly affects state agencies purchasing opioid reversal medications and pharmaceutical companies that settled opioid-related lawsuits. The bill died in committee in May 2025 and did not become law.
HB 310 proposed establishing a state matching grant program to increase community shelter capacity for the homeless population. Administered by the Department of Public Health and Human Services, these grants would help local governments and eligible nonprofit organizations. The funds would specifically target services for senior citizens, veterans, survivors of domestic violence, youth transitioning from foster care, and individuals with mental health or substance use disorders. Applicants would be required to provide matching funds and collaborate with existing homelessness service providers. The bill appropriated $2 million from the general fund for the program, which was set to operate from July 2025 to June 2027.
HB 386 directs the Department of Public Health and Human Services to apply for the reinstatement of 12-month continuous Medicaid eligibility for specific groups. This would affect parents, caretaker relatives, and adults covered under Medicaid expansion. The department is required to submit amendments to existing federal waivers by September 30, 2025, to restore this continuous eligibility, which was previously allowed before certain waiver changes in 2021 and 2022. The bill would take effect immediately upon passage and approval.
HB 385 proposed establishing the School Mental Health Promotion Pilot Program, administered by the Office of Public Instruction. This program would have provided grants to Montana school districts to implement innovative, student-led, and locally determined initiatives aimed at improving student mental health. Districts applying for grants would have needed to demonstrate specific needs, broad community support in their application development, and plans for mental health promotion activities and program evaluation. The bill proposed annual grants ranging from $10,000 to $50,000 for a two-year period, with $250,000 appropriated annually from the general fund. The program was set to terminate on June 30, 2029.
HB 273, the "Montana Medical Debt Patient Protection Act," aimed to limit how health care providers and third-party collectors pursue medical debt from patients in Montana. The bill would have prohibited certain collection actions, including wage garnishment, placing liens on a patient's primary residence, and reporting adverse information to credit agencies. It also mandated a 180-day waiting period after the first bill before "extraordinary collection actions," such as filing lawsuits or selling debt, could begin, along with requiring a 30-day notice to the patient. Additionally, it sought to provide patients with an opportunity to appeal insurance decisions before a bill went to collections.
The provided bill text, identified as Senate Bill 382, focuses on revising laws related to immunization exemptions, which differs from the title "Establish the specie legal tender act" for HB 382.
Based on the provided text, this bill mandates that various entities, including state agencies, schools, child care facilities, and licensed health care providers, must accept religious or informed consent exemptions for required immunizations, injections, or medications for employment or attendance. It establishes that denying such an exemption is an unlawful discriminatory practice. Non-compliant entities could face a loss of state funding, and individuals denied an exemption may file complaints and seek compensatory damages. The bill also clarifies and strengthens the existing provisions for religious, medical, and informed consent exemptions for school attendance.
House Bill 371 aimed to prohibit the administration of gene-based vaccines, including those using messenger RNA (mRNA) or deoxyribonucleic acid (DNA) technology, to humans within the state of Montana. The bill proposed that anyone providing or administering such a vaccine would be guilty of a misdemeanor, facing a $500 fine for each incident. It also required the relevant licensure board to review the license of any professional who violated this prohibition. This legislation would directly affect healthcare providers and individuals seeking these specific types of vaccines in Montana.
HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.
